Framebased-Frameless_DV_2017

Progression-free

survival

Gomez D, Lancet Oncol 2016

Oligometastatic NSCLC without progression after

first-line systemic therapy:

A multicentre,

randomised, controlled, phase 2 study

11·9 months

(90% CI 5·72–20·90) versus

3·9 months

(2·30–6·64) in the

maintenance group (HR 0·35 [90% CI 0·18–0·66]; log-rank p=0·0054).

Local consolidative therapy regimens used

• Hypofractionated RT or SABR in 48% (12 patients)

• Surgery and RT for 24%

• Chemo-RT for 8%

• Hypofractionated RT and CT-RT for 12%

• Surgery only for 4%